DE60123381D1 - Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung - Google Patents

Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung

Info

Publication number
DE60123381D1
DE60123381D1 DE60123381T DE60123381T DE60123381D1 DE 60123381 D1 DE60123381 D1 DE 60123381D1 DE 60123381 T DE60123381 T DE 60123381T DE 60123381 T DE60123381 T DE 60123381T DE 60123381 D1 DE60123381 D1 DE 60123381D1
Authority
DE
Germany
Prior art keywords
dose forms
new dose
substituted benzimidazoles
omeprazole
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123381T
Other languages
English (en)
Other versions
DE60123381T2 (de
Inventor
Jeffrey O Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri System
Original Assignee
University of Missouri System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23911053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60123381(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Missouri System filed Critical University of Missouri System
Publication of DE60123381D1 publication Critical patent/DE60123381D1/de
Application granted granted Critical
Publication of DE60123381T2 publication Critical patent/DE60123381T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
DE60123381T 2000-01-11 2001-01-10 Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung Expired - Lifetime DE60123381T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/481,207 US6489346B1 (en) 1996-01-04 2000-01-11 Substituted benzimidazole dosage forms and method of using same
US481207 2000-01-11
PCT/US2001/000796 WO2001051050A1 (en) 2000-01-11 2001-01-10 Novel substituted benzimidazole dosage forms and method of using same

Publications (2)

Publication Number Publication Date
DE60123381D1 true DE60123381D1 (de) 2006-11-09
DE60123381T2 DE60123381T2 (de) 2007-08-09

Family

ID=23911053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123381T Expired - Lifetime DE60123381T2 (de) 2000-01-11 2001-01-10 Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung

Country Status (21)

Country Link
US (7) US6489346B1 (de)
EP (4) EP2305259A1 (de)
JP (4) JP2003519656A (de)
KR (1) KR100679767B1 (de)
AT (1) ATE340574T1 (de)
AU (2) AU782488B2 (de)
BR (1) BR0107565A (de)
CA (1) CA2396159C (de)
CY (1) CY1107512T1 (de)
DE (1) DE60123381T2 (de)
DK (1) DK1246622T3 (de)
ES (1) ES2275650T3 (de)
IL (2) IL150696A0 (de)
MX (1) MXPA02006780A (de)
NO (1) NO331542B1 (de)
NZ (1) NZ520121A (de)
PL (1) PL201906B1 (de)
PT (1) PT1246622E (de)
RU (1) RU2279276C2 (de)
WO (1) WO2001051050A1 (de)
ZA (1) ZA200205512B (de)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6537525B1 (en) * 1997-01-29 2003-03-25 Douglas H. West Medicated chewing-gum
AU742620B2 (en) * 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
ATE481090T1 (de) * 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
US6708822B1 (en) * 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
JP2005529059A (ja) 2001-09-28 2005-09-29 マクニール−ピーピーシー・インコーポレイテッド 改質した放出用の投薬形態
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
WO2003053221A2 (en) * 2001-12-19 2003-07-03 Eisai Co. Ltd Methods using proton pump inhibitors
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
WO2004004682A2 (en) * 2002-07-02 2004-01-15 Laboratorios S.A.L.V.A.T., S.A. Stable oily suspension of microgranules
US20040081671A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20060135406A1 (en) * 2002-10-14 2006-06-22 Sabina Glozman Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20060140985A1 (en) * 2003-01-10 2006-06-29 Zhong Zhang Lansoprazole formulations and related processes and methods
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
AU2005204242B2 (en) * 2003-02-20 2009-10-01 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
MXPA06000524A (es) 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2005011591A2 (en) * 2003-08-01 2005-02-10 Altana Pharma Ag Method for the treatment of sleep disorders
WO2005018640A1 (en) * 2003-08-20 2005-03-03 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
AU2004271747A1 (en) * 2003-09-18 2005-03-24 Altana Pharma Ag Use of known active ingredients as radical scavengers
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005032554A1 (en) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20070082047A1 (en) * 2003-11-07 2007-04-12 Masae Sugaya Solid preparation
CA2552440A1 (en) * 2003-12-30 2005-07-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
DE102004007854A1 (de) * 2004-02-17 2005-09-01 Hexal Ag Stabile, wässrige Formulierung für Benzimidazole
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2005115474A1 (en) 2004-05-25 2005-12-08 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1750677B1 (de) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
FR2873924A1 (fr) * 2004-08-03 2006-02-10 Promindus Actions Promotionnel Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s) et sa preparation
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060046998A1 (en) * 2004-08-25 2006-03-02 Fairfield Clinical Trials, Llc Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease
WO2006108208A1 (en) * 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
AU2005306579B2 (en) * 2004-11-22 2012-01-19 Immuron Limited Bioactive compositions
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
CN101128186B (zh) * 2005-02-03 2013-07-03 奈科明制药有限公司 制备含钙组合物的快速湿聚结方法
US7312217B2 (en) 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
US20060210480A1 (en) * 2005-03-21 2006-09-21 Shaheen Hamdy Treatment of reduction of dysphagia
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006116582A2 (en) * 2005-04-26 2006-11-02 The Curators Of The University Of Missouri Pharmaceutical compositions comprising a substituted benzimidazole, buffering agent and vitamin b12
US10307581B2 (en) * 2005-04-27 2019-06-04 C. R. Bard, Inc. Reinforced septum for an implantable medical device
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US20100086572A1 (en) * 2005-05-13 2010-04-08 Rajneesh Taneja Rational ppi dosage forms
WO2006123207A2 (en) * 2005-05-20 2006-11-23 Vecta, Ltd. A kit for inhibiting gastric acid secretion having an adjustable amount of ph regulating agent
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃H+,K+−ATPaseの重水素化阻害剤
EP3449928A1 (de) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
JP2009519334A (ja) * 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20090175959A1 (en) 2005-12-28 2009-07-09 Takeda Pharmaceutical Company Limited Controlled Release Solid Preparation
WO2007099433A2 (en) * 2006-02-28 2007-09-07 Wockhardt Ltd Delayed release dosage form of pantoprazole or salt thereof
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
RU2467747C2 (ru) * 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术(石家庄)有限公司 一种奥美拉唑组合物及其制备方法
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080145423A1 (en) * 2006-12-14 2008-06-19 Ajmal Ali Khan Chewable tablet and method of formulating
US20080166423A1 (en) * 2007-01-06 2008-07-10 Renjit Sundharadas Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US20090023771A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
EP2254420A4 (de) 2008-02-20 2012-02-15 Targia Pharmaceuticals Zns-pharmazeutika und verfahren für ihre verwendung
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
WO2009123580A1 (en) * 2008-04-01 2009-10-08 Schering-Plough Healthcare Products, Inc. Chewable tablet and method of formulating
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
NZ591940A (en) * 2008-10-10 2013-08-30 Alvine Pharmaceuticals Inc Dosage forms that facilitate rapid activation of zymogen
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
CA2753214C (en) 2009-02-27 2017-07-25 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
KR20120093140A (ko) * 2009-06-25 2012-08-22 포젠 인크. 아스피린 치료를 필요로 하는 환자의 치료 방법
AU2010276404A1 (en) * 2009-07-20 2012-02-02 Vetegen, Llc A stable pharmaceutical omeprazole formulation for oral administration
CA2769030C (en) 2009-07-30 2016-05-10 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
TWI463998B (zh) * 2009-12-31 2014-12-11 Synmosa Biopharma Corp Amoxicillin and clomycin have a high absorption rate of pharmaceutical ingredients
EP2523654A4 (de) * 2010-01-11 2014-08-06 Mohamed Shafee Muneera Zusammensetzungen mit sofortiger freisetzung aus säurelabilen substanzen
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
US9675102B2 (en) * 2010-09-07 2017-06-13 R. J. Reynolds Tobacco Company Smokeless tobacco product comprising effervescent composition
EP3669841A1 (de) * 2011-11-15 2020-06-24 KCI Licensing, Inc. Medizinische verbände, systeme und verfahren mit thermisch optimierter dampfübertragung
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
EP2649989B1 (de) 2012-04-13 2017-10-18 King Saud University Verfahren zur Herstellung einer Feststoffdispersion, damit hergestellte Feststoffdispersion und Verwendung dafür
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20140371174A1 (en) 2013-06-12 2014-12-18 The Procter & Gamble Company Effervescent Dosage Form
IN2014DN10385A (de) * 2012-06-12 2015-08-14 Procter & Gamble
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
US20140323419A1 (en) * 2013-04-24 2014-10-30 Tat-Kin Tsang High efficacy combination therapy for helicobacter pylori eradication and packaging for the distribution and use thereof
CN103784414B (zh) * 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种埃索美拉唑肠溶片及其制备方法
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
CA2987034C (en) * 2015-05-29 2023-03-07 Johnson & Johnson Consumer Inc. Use of an organic citrus extract with high antimicrobial capacity and xylitol as a preservative system in liquids, emulsions, suspensions, creams and antacids
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US11207307B2 (en) 2016-06-16 2021-12-28 Azurity Pharmaceuticals, Inc. Composition and method for proton pump inhibitor suspension
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
EP3720844A4 (de) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation Arzneimittelzusammensetzungen
KR102080023B1 (ko) * 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
CN108686194A (zh) * 2018-08-20 2018-10-23 李时珍(广州)健康科技有限公司 一种改善小儿肠胃功能的中药泡浴组合物、其制备方法及应用
WO2020040438A1 (ko) 2018-08-23 2020-02-27 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
KR102290295B1 (ko) 2019-07-26 2021-08-17 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
TW202126301A (zh) 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
KR102573842B1 (ko) 2020-02-21 2023-09-01 주식회사 종근당 방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물
KR20210012881A (ko) 2020-02-28 2021-02-03 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006862A (en) * 1932-12-29 1935-07-02 American Anode Inc Manufacture of articles from aqueous rubber dispersions
US4045564A (en) 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
US4252790A (en) * 1974-10-23 1981-02-24 Interx Research Corporation Method for treating gastric ulcer-prone patients
JPS52102416A (en) 1976-02-19 1977-08-27 Okawara Mfg Granule making method of herb medicine and like
IN148930B (de) 1977-09-19 1981-07-25 Hoffmann La Roche
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6043064B2 (ja) 1979-11-28 1985-09-26 ウェルファイド株式会社 新規イソオキサゾ−ル誘導体
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
JPS57212180A (en) 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
US4472409A (en) 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
RO88351A3 (ro) 1984-04-26 1986-04-30 Intreprinderea De Medicamente"Terapia",Ro Compozitie pentru tratamentul afectiunilor gastroduodenale
SE8403179D0 (sv) 1984-06-13 1984-06-13 Haessle Ab New compounds
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS62145083A (ja) 1985-12-18 1987-06-29 Yoshitomi Pharmaceut Ind Ltd 縮合イミダゾ−ル誘導体
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
AU619444B2 (en) * 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
SE8604566D0 (sv) 1986-10-27 1986-10-27 Haessle Ab Novel compunds
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5215974A (en) 1986-11-21 1993-06-01 Aktiebolaget Hassle Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-acid secretion related diseases
DE3887417T2 (de) 1987-03-25 1994-05-26 Yoshitomi Pharmaceutical Thienocinnolinverbindungen und deren verwendung als heilmittel.
NZ224252A (en) 1987-04-21 1991-09-25 Erba Carlo Spa An anthracycline glycoside and its preparation
WO1989000566A1 (en) 1987-07-21 1989-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compounds and medicinal use thereof
ES2043766T3 (es) 1987-11-11 1994-01-01 Pharmascience Lab Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua.
GB8809421D0 (en) 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
AU3683889A (en) 1988-06-30 1990-01-23 Upjohn Company, The Transdermal antisecretory agents for gastrointestinal disease
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
WO1990003380A1 (en) 1988-09-21 1990-04-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienocycloheptapyridazine compounds and medicinal uses thereof
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
SE8804628D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New compounds
IE64199B1 (en) 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
JP2694361B2 (ja) 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
ATE114114T1 (de) 1989-02-10 1994-12-15 Takeda Chemical Industries Ltd Verwendung von benzimidazol-derivaten als antibakterielle mittel.
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
SE8903563D0 (sv) 1989-10-26 1989-10-26 Haessle Ab A novel dissolution system
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
US5254682A (en) * 1989-12-08 1993-10-19 Merck & Co., Inc. Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
CA2038716A1 (en) 1990-03-28 1991-09-29 Yoshio Ueda Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide-containing preparation, stabilizing method thereof and drug stabilized thereby
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
EP0461930B1 (de) * 1990-06-15 1995-09-13 Merck & Co. Inc. Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse
CA2083606C (en) 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
ATE145208T1 (de) 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical Kondensierte thiophenverbindungen und deren verwendung
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
EP0548103B1 (de) 1990-09-14 2001-12-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
US5232706A (en) 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
EP0567643A4 (de) 1991-01-16 1995-07-19 Yoshitomi Pharmaceutical Neues pyridinderivat sowie seine verwendung als selektives arzneimittel.
US5244670A (en) 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
SE502569C2 (sv) 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
NZ244301A (en) 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
WO1993005770A1 (en) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Long-acting preparation
JPH05117268A (ja) 1991-10-22 1993-05-14 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
US5339700A (en) 1991-12-16 1994-08-23 Isco, Inc. Sample collector
TW224049B (de) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
TW276996B (de) 1992-04-24 1996-06-01 Astra Ab
US5504082A (en) 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) * 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
US5447918A (en) 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
NZ254237A (en) 1992-07-28 1995-12-21 Astra Ab Injectable solution of a 2-[(2-pyridyl)methylsulphinyl]-benzimidazole or a salt thereof; an injection kit
JPH0656665A (ja) 1992-08-03 1994-03-01 Nippon Chemiphar Co Ltd イミダゾール誘導体を含有する胃溶性抗潰瘍剤
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
CA2128820A1 (en) 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5965162A (en) * 1993-09-10 1999-10-12 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
WO1995007913A1 (fr) 1993-09-17 1995-03-23 Meiji Milk Products Co., Ltd. Agent antibacterien et antifongique
AU7833194A (en) 1993-09-20 1995-04-10 Procter & Gamble Company, The Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
JP3710473B2 (ja) 1993-10-12 2005-10-26 三菱ウェルファーマ株式会社 腸溶性顆粒含有錠剤
US5762962A (en) * 1994-10-05 1998-06-09 Warner-Lambert Company Antacid pharmaceutical composition
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
IS4232A (is) 1993-12-06 1995-06-07 Astra Aktiebolag Súbstitúerað bensimidasól, aðferðir við framleiðslu þess og lyfjafræðileg notkun
US5714505A (en) 1994-01-05 1998-02-03 Astra Aktiebolag Method for treatment of psoriasis, by omeprazole or related compounds
KR0179401B1 (ko) 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
ES2136157T3 (es) * 1994-03-01 1999-11-16 Gerhard Gergely Producto granular o comprimido que contiene un sistema efervescente y una sustancia farmaceutica activa, asi como un procedimiento para su preparacion.
DE670160T1 (de) 1994-03-01 1996-03-14 Gerhard Gergely Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung.
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
TNSN95062A1 (fr) 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
WO1995032957A1 (en) 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
ES2100142T3 (es) 1994-07-08 2002-03-01 Astrazeneca Ab Forma de dosificacion en tabletas i constituida por unidades multiples.
MX9700152A (es) 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
SE9404192D0 (sv) 1994-12-02 1994-12-02 Astra Ab New process
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
WO1996038175A1 (en) 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9503102D0 (sv) 1995-09-08 1995-09-08 Astra Ab Aseptic transfer
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
JPH11513679A (ja) 1995-10-17 1999-11-24 アストラ・フアーマシユウテイカルズ・リミテツド 薬剤活性キナゾリン化合物
SE521100C2 (sv) 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19628643A1 (de) 1996-07-16 1998-01-22 Merck Patent Gmbh Werkstoffe für die Herstellung von Transportbehältern
US5766622A (en) 1996-08-14 1998-06-16 The Procter & Gamble Company Inhibiting undesirable taste in oral compositions
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
US5885594A (en) 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
AU7375598A (en) 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US5939091A (en) 1997-05-20 1999-08-17 Warner Lambert Company Method for making fast-melt tablets
US20010053387A1 (en) 1997-05-23 2001-12-20 Hamied Yusuf Khwaja Benzimidazole pharmaceutical composition and process of prepatation
SE9702000D0 (sv) 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE19752843C2 (de) 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
AU1671799A (en) 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
HUP0100043A2 (hu) 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions
IT1299198B1 (it) 1998-03-05 2000-02-29 Nicox Sa Sali nitrati di farmaci antiulcera
EP1004305B1 (de) 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilisierte zusammenstellungen die benzimidazole enthalten
JP4127740B2 (ja) 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB2338896B (en) 1998-07-02 2003-05-21 Reckitt & Colmann Prod Ltd Chewable Capsules
US6503431B1 (en) * 1998-07-08 2003-01-07 Mitsui Chemicals Inc Process for manufacturing an extruded article and an extruded article
US6166213A (en) 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
DE69930648T2 (de) 1998-08-12 2006-12-21 Altana Pharma Ag Orale darreichungsform für pyridin-2-ylmethylsulfinyl-1h-benzimidazole
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
ATE232382T1 (de) 1998-09-10 2003-02-15 Nycomed Danmark As Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
WO2000026185A2 (en) * 1998-10-30 2000-05-11 The Curators Of The University Of Missouri Omeprazole solution and method of using same
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
DE69918854T2 (de) 1998-11-18 2005-07-21 Astrazeneca Ab Verbesserter chemischer prozess und eine pharmazeutische zubereitung
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804314D0 (sv) 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
KR100299562B1 (ko) * 1998-12-29 2001-11-22 우재영 안정성을극대화시킨5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸유도체함유미세과립
JP2000212180A (ja) 1999-01-21 2000-08-02 Welfide Corp キノリン化合物
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
ES2216870T3 (es) 1999-02-23 2004-11-01 MERCK & CO., INC. Composicion farmaceutica que contiene inhibidores de la bomba de protones.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9911017D0 (en) 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
ATE316076T1 (de) 1999-06-22 2006-02-15 Neurosearch As Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
CN1611489A (zh) 1999-06-28 2005-05-04 三共株式会社 笨并咪唑化合物的合成中间体及其制造方法
ES2240113T3 (es) * 1999-06-30 2005-10-16 Takeda Pharmaceutical Company Limited Cristales de lansoprazol.
WO2001003707A1 (en) 1999-07-12 2001-01-18 Smithkline Beecham Corporation Heartburn treatment
US6262086B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
JP2003507721A (ja) 1999-08-26 2003-02-25 エイエイアイファーマ・インコーポレイテッド 組成物中のオメプラゾールの異性体比のft−ラマン分光測定
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) * 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
AU2878801A (en) 1999-10-01 2001-05-10 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
SE9904044D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
MXPA02012659A (es) * 2000-06-26 2003-09-22 Lilly Icos Llc Derivados de pirazindiona condensados.
CA2386716C (en) 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
WO2002026210A2 (en) 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US6608091B2 (en) * 2001-04-20 2003-08-19 Linda B. Whittall Process for purifying 6-methoxy omeprazole
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
WO2003063927A2 (en) 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
US20040010151A1 (en) * 2002-03-27 2004-01-15 Nina Finkelstein Lansoprazole polymorphs and processes for preparation thereof
AR045062A1 (es) 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas

Also Published As

Publication number Publication date
ATE340574T1 (de) 2006-10-15
BR0107565A (pt) 2003-02-11
EP1246622A1 (de) 2002-10-09
CY1107512T1 (el) 2013-03-13
WO2001051050A1 (en) 2001-07-19
AU782488B2 (en) 2005-08-04
ZA200205512B (en) 2004-02-10
EP1430895A1 (de) 2004-06-23
JP2003519656A (ja) 2003-06-24
NO20023313L (no) 2002-08-30
KR100679767B1 (ko) 2007-02-07
US6780882B2 (en) 2004-08-24
AU2005229686A1 (en) 2005-12-01
JP2014133775A (ja) 2014-07-24
DK1246622T3 (da) 2007-01-29
EP2305259A1 (de) 2011-04-06
US20030144306A1 (en) 2003-07-31
US20030118669A1 (en) 2003-06-26
JP5944943B2 (ja) 2016-07-05
JP4991432B2 (ja) 2012-08-01
KR20020089322A (ko) 2002-11-29
EP1246622B1 (de) 2006-09-27
RU2002121623A (ru) 2004-03-20
EP1246622A4 (de) 2004-06-16
AU2005229686B2 (en) 2009-08-20
RU2279276C2 (ru) 2006-07-10
US6489346B1 (en) 2002-12-03
PL201906B1 (pl) 2009-05-29
US20040058018A1 (en) 2004-03-25
AU3276701A (en) 2001-07-24
JP2007277271A (ja) 2007-10-25
CA2396159A1 (en) 2001-07-19
PT1246622E (pt) 2007-01-31
US20050042304A1 (en) 2005-02-24
US20090022796A1 (en) 2009-01-22
EP1927354A1 (de) 2008-06-04
US20030215527A1 (en) 2003-11-20
ES2275650T3 (es) 2007-06-16
DE60123381T2 (de) 2007-08-09
IL150696A (en) 2009-05-04
MXPA02006780A (es) 2003-10-06
NZ520121A (en) 2005-04-29
US7399772B2 (en) 2008-07-15
CA2396159C (en) 2007-11-13
JP2012136531A (ja) 2012-07-19
NO20023313D0 (no) 2002-07-09
PL357144A1 (en) 2004-07-12
IL150696A0 (en) 2003-02-12
NO331542B1 (no) 2012-01-23

Similar Documents

Publication Publication Date Title
DE60123381D1 (de) Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung
DE69801045D1 (de) Pharmazeutische zusammensetzung zur oralen verabreichung von einem n-piperidin-3-pyrazolcarboxamid-derivat, dessen salzen und deren solvaten
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
EE200000315A (et) Heterotsüklilised ühendid maohappesekretsiooni inhibeerimiseks, protsess nende valmistamiseks ja ravimkoostised
DE69921941D1 (de) Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln
DE69928554D1 (de) Therapeutische formulierung enthaltende dosierungsform
DE69940080D1 (de) Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs
MA26530A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques; procede pour leur preparation et compostions pharmaceutiques les contenant.
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
EE9700014A (et) Uus peroraalne ravimvorm, mis sisaldab omeprasooli magneesiumsoola
ATE445409T1 (de) Zusammensetzungen mit matrixproteinen zur regeneration von dentin
MA26736A1 (fr) Precurseurs medicamenteux mutuels d'amlodipine et d'atorvastatine, procede pour leur preparation et compositions pharmaceutiques les contenant
BG105275A (en) Tan-1057 derivatives
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
FR2677021B1 (fr) Nouveaux derives de thiazole antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
ATE323097T1 (de) Neue 5-thio-ss-d-xylopyranosidderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen und deren therapeutische verwendung
FR2869610B1 (fr) Derives de l'acide pentenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
FR2777280B1 (fr) Derives de ginkgolides, leur procede de preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
8364 No opposition during term of opposition